{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:00:52Z","timestamp":1780977652366,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.msard.2026.107279","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T16:20:50Z","timestamp":1779812450000},"page":"107279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Neuropsychological symptoms and subclinical disease activity in multiple sclerosis patients receiving high-efficacy therapy"],"prefix":"10.1016","volume":"111","author":[{"given":"Pauline","family":"M\u00fchlenbrock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Axhausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"J\u00fcnemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidrun H.","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Kampling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Zara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5171-4845","authenticated-orcid":false,"given":"Steffen","family":"Pfeuffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107279_bib0024","doi-asserted-by":"crossref","first-page":"e2216","DOI":"10.1212\/WNL.0000000000008617","article-title":"Disability worsening among persons with multiple sclerosis and depression","volume":"93","author":"Binzer","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107279_bib0009","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1093\/brain\/awab241","article-title":"The potential of serum neurofilament as biomarker for multiple sclerosis","volume":"144","author":"Bittner","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.msard.2026.107279_bib0011","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jns.2016.11.067","article-title":"Prevalence of depression and anxiety in Multiple Sclerosis: a systematic review and meta-analysis","volume":"372","author":"Boeschoten","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2026.107279_bib0010","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1176\/appi.ajp.159.11.1862","article-title":"Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample","volume":"159","author":"Chwastiak","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.msard.2026.107279_bib0023","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jad.2020.07.073","article-title":"Predictors of emotional distress in people with multiple sclerosis: a systematic review of prospective studies","volume":"276","author":"Fisher","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.msard.2026.107279_bib0031","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1186\/s12888-024-06051-0","article-title":"Neurofilament light chain as a promising biomarker for depression diagnosis: a systematic review and meta-analysis","volume":"24","author":"Habibzadeh","year":"2024","journal-title":"BMC. Psychiatry"},{"key":"10.1016\/j.msard.2026.107279_bib0003","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107279_bib0002","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus Teriflunomide in Multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107279_bib0005","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107279_bib0027","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jns.2016.03.024","article-title":"Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: an analysis from the EPOC (Evaluate Patient OutComes) trial","volume":"365","author":"Hunter","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2026.107279_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104604","article-title":"Physical disability, anxiety and depression in people with MS: an internet-based survey via the UK MS Register","volume":"9","author":"Jones","year":"2014","journal-title":"PLoS. One"},{"key":"10.1016\/j.msard.2026.107279_bib0006","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2026.107279_bib0008","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2026.107279_bib0026","doi-asserted-by":"crossref","first-page":"107","DOI":"10.7224\/1537-2073.2012-036","article-title":"Relationship between disease-modifying therapy and depression in multiple sclerosis","volume":"15","author":"Kirzinger","year":"2013","journal-title":"Int. J. MS. Care"},{"key":"10.1016\/j.msard.2026.107279_bib0019","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.msard.2026.107279_bib0018","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/PSY.0000000000000322","article-title":"Patient health questionnaire anxiety and depression scale: initial validation in three clinical trials","volume":"78","author":"Kroenke","year":"2016","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.msard.2026.107279_bib0020","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/MLR.0b013e318160d093","article-title":"Validation and standardization of the Generalized Anxiety Disorder screener (GAD-7) in the general population","volume":"46","author":"L\u00f6we","year":"2008","journal-title":"Med. Care"},{"key":"10.1016\/j.msard.2026.107279_bib0028","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1177\/13524585211031128","article-title":"Risk of depression in multiple sclerosis across disease-modifying therapies","volume":"28","author":"Longinetti","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107279_bib0007","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.msard.2026.107279_bib0021","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/1352458514564487","article-title":"The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review","volume":"21","author":"Marrie","year":"2015","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.107279_bib0015","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/ana.27143","article-title":"Different treatment outcomes of multiple sclerosis patients receiving Ocrelizumab or Ofatumumab","volume":"97","author":"Meuth","year":"2025","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2026.107279_bib0029","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.msard.2017.10.004","article-title":"Treating depression in multiple sclerosis with antidepressants: a brief review of clinical trials and exploration of clinical symptoms to guide treatment decisions","volume":"18","author":"Nathoo","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107279_bib0001","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107279_bib0013","article-title":"Multiple sclerosis: emerging epidemiological trends and redefining the clinical course","volume":"44","author":"Portaccio","year":"2024","journal-title":"Lancet Reg. Health - Eur."},{"key":"10.1016\/j.msard.2026.107279_bib0012","doi-asserted-by":"crossref","first-page":"125","DOI":"10.31887\/DCNS.2007.9.2\/mpucak","article-title":"Neuropsychiatric manifestations of depression in multiple sclerosis: neuroinflammatory, neuroendocrine, and neurotrophic mechanisms in the pathogenesis of immune-mediated depression","volume":"9","author":"Pucak","year":"2007","journal-title":"Dialogues. Clin. Neurosci."},{"key":"10.1016\/j.msard.2026.107279_bib0030","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252313153","article-title":"Effect of Natalizumab on sNfL and sGFAP levels in Multiple sclerosis patients","volume":"25","author":"Sainz-Amo","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2026.107279_bib0025","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/ana.27034","article-title":"Smouldering-associated worsening in multiple sclerosis: an international consensus statement on definition, biology, clinical implications, and future directions","volume":"96","author":"Scalfari","year":"2024","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2026.107279_bib0004","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","article-title":"Treatment escalation vs immediate initiation of highly effective Treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies","volume":"78","author":"Spelman","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2026.107279_bib0014","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107279_bib0017","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","article-title":"2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis","volume":"20","author":"Wattjes","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107279_bib0016","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/jnnp-2024-335673","article-title":"Association of body mass index and clinical response in patients receiving ofatumumab for treatment of multiple sclerosis","volume":"96","author":"Winter","year":"2025","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826003159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826003159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T03:39:12Z","timestamp":1780976352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826003159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":31,"alternative-id":["S2211034826003159"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107279","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuropsychological symptoms and subclinical disease activity in multiple sclerosis patients receiving high-efficacy therapy","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107279","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107279"}}